PTJ
PRME icon

Paul Tudor Jones’s Prime Medicine PRME Stock Holding History

Paul Tudor Jones’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-61,546
Closed -$214K – 4123
2026
Q1 		$214K Buy
+61,546
New +$234K ﹤0.01% 3338
2025
Q4 		– Sell
-62,981
Closed -$349K – 3945
2025
Q3 		$349K Buy
+62,981
New +$256K ﹤0.01% 2886
2025
Q2 		– Sell
-60,368
Closed -$120K – 3659
2025
Q1 		$120K Buy
+60,368
New +$154K ﹤0.01% 2926
2024
Q2 		– Sell
-61,295
Closed -$429K – 2699
2024
Q1 		$429K Buy
+61,295
New +$465K ﹤0.01% 1713

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Paul Tudor Jones's PRME Position: Q2 2026 in Review

Paul Tudor Jones sold out of Prime Medicine (PRME) in Q2 2026, closing a stake of 61,546 shares — an estimated $214K sold.

Paul Tudor Jones first reported a position in PRME in Q1 2024 and held it in 4 quarters. The position peaked at $429K in Q1 2024. 186 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Paul Tudor Jones reported no remaining Prime Medicine position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 61,546 Prime Medicine shares in Q2 2026, an estimated $214K.
  • Paul Tudor Jones first reported a position in Prime Medicine in Q1 2024 and held it in 4 quarters.
  • Paul Tudor Jones's Prime Medicine position peaked at $429K in Q1 2024.
  • 186 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.